Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: William L. Molair II who wrote (7874)	11/29/1998 6:43:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Don't know. Wish I did.

To: William L. Molair II who wrote (7874)	11/29/1998 8:38:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Willaim, I will attempt a answer. If dsmb meningo causes a halt of some sort, you should get info fairly quickly. If Dsmb meningo says lets review the trial en toto, then its 90 some days past then till we find out which puts us in march-april. Now mind you we have dsmb pneumonia/ards in feb-march timeframe. And we also have liver results prending. And we also have hu1124 (another c3 type drug) pending about january. And we also have another indication pending. Plus God knows what else. So you all can look to meningo, but we might see action elsewhere before then. Hope that helps :-) All disclaimers on everything. Consider nothing as fact. :-)

To: William L. Molair II who wrote (7874)	11/29/1998 9:49:00 PM
From: Arthur Radley	Respond to of 17367

Quoting from their November 13 news release....."The DSMB overseeing the meningococcemia Phase III trial met in September for a third interim analysis of data from the trial. There were no safety concerns with the trial, and the DSMB recommended the trial continue. The trial has enrolled 285 patients to date at 15 centers in the United Kingdom and the US, and is expected to conclude in early 1999"...."XOMA clinicians, scientist and managers have been reveiwing several new medical indications for NEUPREX and the company plans to take at least one into the clinic in the next few months."....."The phase III trial in patients suffering hemorrhage due to trauma has so far enrolled more that 450 patients at 40 trauma centers in the United States. An interim analysis of data from the first 400 patients will take place early in 1999." As you can see, no firm dates as to when news will be forthcoming, other than early 1999, but when it starts it appears that the "cup will runneth over".(:>) However, in this same news release they mention the hiring of two separate firms to seek licensing partners for Mycoprex and I-PREX. Depending on the major drug companies and their eagerness to lock up these products, this news could come anytime and would be welcomed.